These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

109 related items for PubMed ID: 10412269

  • 21. A multifactorial prognostic model for adult soft tissue sarcoma considering clinical, histopathological and molecular data.
    Würl P, Lautenschläger C, Meye A, Schmidt H, Bache M, Rath FW, Schönfelder M, Taubert H.
    Anticancer Res; 2000; 20(3B):2065-72. PubMed ID: 10928153
    [Abstract] [Full Text] [Related]

  • 22. Distinct mdm2/p53 expression patterns in liposarcoma subgroups: implications for different pathogenetic mechanisms.
    Pilotti S, Della Torre G, Lavarino C, Di Palma S, Sozzi G, Minoletti F, Rao S, Pasquini G, Azzarelli A, Rilke F, Pierotti MA.
    J Pathol; 1997 Jan; 181(1):14-24. PubMed ID: 9071998
    [Abstract] [Full Text] [Related]

  • 23. Immunohistochemical expression of p53, MDM2, Ki-67 and PCNA in central giant cell granuloma and giant cell tumor.
    de Souza PE, Paim JF, Carvalhais JN, Gomez RS.
    J Oral Pathol Med; 1999 Feb; 28(2):54-8. PubMed ID: 9950250
    [Abstract] [Full Text] [Related]

  • 24. Analysis of p53 and mdm2 proteins in malignant fibrous histiocytoma in absence of gene alteration: prognostic significance.
    Molina P, Pellín A, Navarro S, Boix J, Carda C, Llombart-Bosch A.
    Virchows Arch; 1999 Dec; 435(6):596-605. PubMed ID: 10628802
    [Abstract] [Full Text] [Related]

  • 25. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
    Patterson H, Gill S, Fisher C, Law MG, Jayatilake H, Fletcher CD, Thomas M, Grimer R, Gusterson BA, Cooper CS.
    Br J Cancer; 1994 Jun; 69(6):1052-8. PubMed ID: 8198970
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Evaluation of p53, PCNA, Ki-67, MDM2 and AgNOR in oral peripheral and central giant cell lesions.
    Souza PE, Mesquita RA, Gomez RS.
    Oral Dis; 2000 Jan; 6(1):35-9. PubMed ID: 10673786
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. In squamous cell carcinoma of the vulva, overexpression of p53 is a late event and neither p53 nor mdm2 expression is a useful marker to predict lymph node metastases.
    Emanuels AG, Koudstaal J, Burger MP, Hollema H.
    Br J Cancer; 1999 Apr; 80(1-2):38-43. PubMed ID: 10389975
    [Abstract] [Full Text] [Related]

  • 34. Analysis of the immunoreactivity of three anti-p53 antibodies and estimation of the relations between p53 status and MDM2 protein expression in ovarian carcinomas.
    Harlozińska A, Bar J, Montenarh M.
    Anticancer Res; 2000 Apr; 20(2A):1049-56. PubMed ID: 10810396
    [Abstract] [Full Text] [Related]

  • 35. MDM2 gene amplification and transcript levels in human sarcomas: relationship to TP53 gene status.
    Flørenes VA, Maelandsmo GM, Forus A, Andreassen A, Myklebost O, Fodstad O.
    J Natl Cancer Inst; 1994 Sep 07; 86(17):1297-302. PubMed ID: 8064888
    [Abstract] [Full Text] [Related]

  • 36. p53 protein expression in breast carcinomas. Comparative study with the wild type p53 induced proteins mdm2 and p21/waf1.
    Giannikaki E, Kouvidou C, Tzardi M, Stefanaki K, Koutsoubi K, Gregoriou M, Zois E, Kakolyris S, Mavroudi C, Delides G, Georgoulias V, Kanavaros P.
    Anticancer Res; 1997 Sep 07; 17(3C):2123-7. PubMed ID: 9216675
    [Abstract] [Full Text] [Related]

  • 37. p53 Mutation and MDM2 amplification in human soft tissue sarcomas.
    Leach FS, Tokino T, Meltzer P, Burrell M, Oliner JD, Smith S, Hill DE, Sidransky D, Kinzler KW, Vogelstein B.
    Cancer Res; 1993 May 15; 53(10 Suppl):2231-4. PubMed ID: 8387391
    [Abstract] [Full Text] [Related]

  • 38. [TP53 gene aberrations in chondromatous neoplasms: correlation with immunohistochemical p53 accumulation and MDM2 expression].
    Blasenbreu S, Baretton GB, Bender C, Haas CJ, Diebold J, Löhrs U.
    Verh Dtsch Ges Pathol; 1998 May 15; 82():284-9. PubMed ID: 10095448
    [Abstract] [Full Text] [Related]

  • 39. Extrapleural solitary fibrous tumor: clinicopathologic study of 17 cases and molecular analysis of the p53 pathway.
    Morimitsu Y, Nakajima M, Hisaoka M, Hashimoto H.
    APMIS; 2000 Sep 15; 108(9):617-25. PubMed ID: 11110050
    [Abstract] [Full Text] [Related]

  • 40. Inactivation of the p53 pathway in prostate cancer: impact on tumor progression.
    Osman I, Drobnjak M, Fazzari M, Ferrara J, Scher HI, Cordon-Cardo C.
    Clin Cancer Res; 1999 Aug 15; 5(8):2082-8. PubMed ID: 10473090
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 6.